ReviewNanomedicine (London, England)2015
Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.
Review in Nanomedicine (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Identification of Cholesterol in Plaques of Atherosclerotic Using Magnetic Resonance Spectroscopy and 1D U-Net Architecture.Molecules (Basel, Switzerland) · 2026Article
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Photodynamic Therapy for Atherosclerosis.International journal of molecular sciences · 2024Review
- Cardiovascular Tissue Engineering Models for Atherosclerosis Treatment Development.Bioengineering (Basel, Switzerland) · 2023Review
- Peptide-Based Nanoparticles for Systemic Extrahepatic Delivery of Therapeutic Nucleotides.International journal of molecular sciences · 2023Review
- Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction.International journal of molecular sciences · 2023Article
- Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury.International journal of molecular sciences · 2023Article
- Nanotechnology as a Versatile Tool forPharmaceutics · 2022Review
- Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets.Oxidative medicine and cellular longevity · 2022Article
- Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Review
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders.Molecules (Basel, Switzerland) · 2021Review
- Imaging of Inflammation in Spinal Cord Injury: Novel Insights on the Usage of PFC-Based Contrast Agents.Biomedicines · 2021Article
- Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis.Frontiers in cardiovascular medicine · 2021Review
- Influence of Oxidation Degree of Graphene Oxide on Its Nuclear Relaxivity and Contrast in MRI.ACS omega · 2020Article
- Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2020Review
- Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model.Molecules (Basel, Switzerland) · 2019Article
- Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy.European cardiology · 2019Review
- Applications of nanoparticles in biomedical imaging.Nanoscale · 2019Review
- Hybrid, metal oxide-peptide amphiphile micelles for molecular magnetic resonance imaging of atherosclerosis.Journal of nanobiotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
As atherosclerosis remains one of the most prevalent causes of patient mortality, the ability to diagnose early signs of plaque rupture and thrombosis represents a significant clinical need. With recent advances in nanotechnology, it is now possible to image specific molecular processes noninvasively with MRI, using various types of nanoparticles as contrast agents. In the context of cardiovascular disease, it is possible to specifically deliver contrast agents to an epitope of interest for detecting vascular inflammatory processes, which serve as predecessors to atherosclerotic plaque development. Herein, we review various applications of nanotechnology in detecting atherosclerosis using MRI, with an emphasis on perfluorocarbon nanoparticles and fluorine imaging, along with theranostic prospects of nanotechnology in cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.